Immune Checkpoint Inhibitor-Associated Optic Neuritis

Jasmine H. Francis; Korey Jaben; Bianca D. Santomasso; Julia Canestraro; David H. Abramson; Paul B. Chapman; Meghan Berkenstock; Mary E. Aronow

doi:10.1016/j.ophtha.2020.05.003

Immune Checkpoint Inhibitor-Associated Optic Neuritis

Jasmine H. Francis, Korey Jaben, Bianca D. Santomasso, Julia Canestraro, David H. Abramson, Paul B. Chapman, Meghan Berkenstock, Mary E. Aronow

School of Medicine

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	1585-1589
Number of pages	5
Journal	Ophthalmology
Volume	127
Issue number	11
DOIs	https://doi.org/10.1016/j.ophtha.2020.05.003
State	Published - Nov 2020

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ophtha.2020.05.003

Cite this

@article{56683051cebd4940bf00ece2da3c6c9a,

title = "Immune Checkpoint Inhibitor-Associated Optic Neuritis",

author = "Francis, {Jasmine H.} and Korey Jaben and Santomasso, {Bianca D.} and Julia Canestraro and Abramson, {David H.} and Chapman, {Paul B.} and Meghan Berkenstock and Aronow, {Mary E.}",

note = "Funding Information: Financial Disclosure(s): The author(s) have made the following disclosure(s): B.D.S.: Consultant – Kite/Gilead, Juno/Celgene, Janssen Pharmaceuticals; Financial support – ACT TherapeuticsP.B.C.: Consultant – Immunocore, Merck & Co., Inc., Cell Medica, Takeda Millennium, Astra Zeneca; Financial support – Pfizer; Equity owner – RgenixSupported by the Fund for Ophthalmic Knowledge; and the National Cancer Institute, National Institutes of Health, Bethesda, Maryland (Cancer Center Support Grant no.: P30 CA008748). The sponsor or funding organization had no role in the design or conduct of this research. Funding Information: Supported by the Fund for Ophthalmic Knowledge; and the National Cancer Institute , National Institutes of Health , Bethesda, Maryland ( Cancer Center Support Grant no.: P30 CA008748 ). The sponsor or funding organization had no role in the design or conduct of this research. ",

year = "2020",

month = nov,

doi = "10.1016/j.ophtha.2020.05.003",

language = "English (US)",

volume = "127",

pages = "1585--1589",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitor-Associated Optic Neuritis

AU - Francis, Jasmine H.

AU - Jaben, Korey

AU - Santomasso, Bianca D.

AU - Canestraro, Julia

AU - Abramson, David H.

AU - Chapman, Paul B.

AU - Berkenstock, Meghan

AU - Aronow, Mary E.

N1 - Funding Information: Financial Disclosure(s): The author(s) have made the following disclosure(s): B.D.S.: Consultant – Kite/Gilead, Juno/Celgene, Janssen Pharmaceuticals; Financial support – ACT TherapeuticsP.B.C.: Consultant – Immunocore, Merck & Co., Inc., Cell Medica, Takeda Millennium, Astra Zeneca; Financial support – Pfizer; Equity owner – RgenixSupported by the Fund for Ophthalmic Knowledge; and the National Cancer Institute, National Institutes of Health, Bethesda, Maryland (Cancer Center Support Grant no.: P30 CA008748). The sponsor or funding organization had no role in the design or conduct of this research. Funding Information: Supported by the Fund for Ophthalmic Knowledge; and the National Cancer Institute , National Institutes of Health , Bethesda, Maryland ( Cancer Center Support Grant no.: P30 CA008748 ). The sponsor or funding organization had no role in the design or conduct of this research.

PY - 2020/11

Y1 - 2020/11

UR - http://www.scopus.com/inward/record.url?scp=85088216488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088216488&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2020.05.003

DO - 10.1016/j.ophtha.2020.05.003

M3 - Article

C2 - 32437864

AN - SCOPUS:85088216488

SN - 0161-6420

VL - 127

SP - 1585

EP - 1589

JO - Ophthalmology

JF - Ophthalmology

IS - 11

ER -

Immune Checkpoint Inhibitor-Associated Optic Neuritis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this